Navigation Links
Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations
Date:7/8/2008

GLP-1 Has Potential to Treat Type 2 Diabetes Using Emisphere's Eligen(R)

Technology

CEDAR KNOLLS, N.J., July 8 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced findings from a clinical study assessing the oral delivery of GLP-1 peptide safely and effectively. The study used a delivery-agent-based approach using Emisphere's Eligen(R) technology, and was conducted at University Hospital in Basel, Switzerland by Christoph Beglinger, M.D., of the Clinical Research Center, Department of Biomedicine Division of Gastroenterology, and Department of Clinical Pharmacology and Toxicology at the hospital.

Prof. Beglinger's study, conducted in 16 healthy male subjects, was designed to explore the pharmacodynamic effects of a single oral dose of GLP-1 administered 15 minutes prior to an oral glucose tolerance test.

For the study, GLP-1 was formulated as a tablet with Emisphere's delivery agent known as SNAC. This was Prof. Beglinger's second clinical study of the compound, and it confirmed his earlier results that SNAC allows for rapid oral absorption of GLP-1. Prof. Beglinger's study also showed that pharmacological levels were achieved after a 2 mg oral dose. The study demonstrated that the oral formulation of GLP-1 stimulated an early increase in fasting insulin and a decrease in fasting glucose as compared to placebo.

"An intravenous or subcutaneous application of GLP-1 is cumbersome and impractical for chronic treatment regimens. Oral application of peptides is, however, difficult as peptides have a low oral bioavailability due to their molecular size and physico-chemical characteristics," said Prof. Beglinger. "Emisphere's oral delivery approach has been developed to overcome some of these issues."

"Prof. Beglinger's study provides yet further evidence in the application of our Eligen(R) technology as a potential solution to critical hurdles in pharmaceutical development. Hopefully, its use with GLP-1 in the treatment of diabetes will improve healthcare for millions of patients," said Michael V. Novinski, President and Chief Executive Officer of Emisphere.

Emisphere's Eligen(R) technology is based on the development of small organic molecules, termed delivery agents or carriers, that interact non-covalently with macromolecules to enable their oral absorption. GLP-1 is rapidly absorbed after oral administration with SNAC. Emisphere announced on June 23, 2008 that it entered a Development and License Agreement with Novo Nordisk A/S focused on the development of oral formulations of Novo Nordisk's proprietary GLP-1 receptor agonists.

ABOUT EMISPHERE TECHNOLOGIES, INC.

Emisphere Technologies, Inc. is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its Eligen(R) Technology. Some of these molecules or compounds can only be given by injection; when combined with our technology; convenient oral versions may be safe, effective and provide significant advantages. The benefits of other compounds are limited due to poor bioavailability, slow on-set of action or variable absorption. In those cases, use of Emisphere's technology can improve the therapeutic effectiveness of the compounds. The Eligen(R) technology can be applied to the oral route of administration as well other delivery pathways. The Web site is: http://www.emisphere.com.

Safe Harbor Statement Regarding Forward-looking Statements

The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, Emisphere's ability to fund such efforts with or without partners, and other risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 1-10615) filed on March 17, 2008 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2008, filed on May 7, 2008.


'/>"/>
SOURCE Emisphere Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
3. Emisphere Technologies Announces Positive Results From Animal Studies on Oral B12 Using eligen(R) Technology
4. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
5. Proof of Concept Study in Second Species Demonstrates Increase in Absorption of Oral B12 Using Emisphere Technology
6. Emisphere Technologies Announces the Launch of a Human Clinical Trial For Oral Parathyroid Hormone (PTH)
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global ... and Gynecology markets with innovative and proprietary products, will ... 31, 2017 after the market close on Tuesday, May ... a conference call and webcast to discuss its financial ... at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, 2017 /PRNewswire/ ... ("Imprimis"), an ophthalmology-focused pharmaceutical company, and Cameron Ehlen ... the signing of a three-year exclusive sales representation ... a dedicated sales team to introduce Imprimis, ophthalmic ... focused in 13 states in the U.S. Midwest. Precision ...
(Date:4/18/2017)... , April 18, 2017 Recursion Pharmaceuticals ... science with machine learning techniques to discover treatments for ... Yolanda Chong as vice president of biology. ... & Johnson in Belgium , where ... focused on applying high-dimensional biological approaches to the small ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... 2017 , ... “Learning to Use Your SPIRITUAL COMPASS To Navigate Life Issues”: ... SPIRITUAL COMPASS To Navigate Life Issues” is the creation of published author, Rachel Jamerson, ... of Directors for CONTACT USA, and former member of the American Association of Christian ...
(Date:4/24/2017)... Miami, FL (PRWEB) , ... April 24, 2017 ... ... John Paul Gallardo, DDS, PA will be attending the 2017 Oral Reconstruction Foundation’s ... 4-6, 2017. , The Oral Reconstruction Foundation will present its annual Global Symposium ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... work wear distributors and International relief organizations across the globe to provide effective ... offers lifestyle and work wear collections via insectshield.com . In the wake ...
(Date:4/24/2017)... ... April 24, 2017 , ... A 2-in-1 ... the same place. From 101 Water Texas, here are the ways in which ... enjoy a continuous supply of pure, fresh, oxygenated water, with both cold and ...
(Date:4/23/2017)... ... April 23, 2017 , ... ... announced the achievement of Cisco Select certification and SMB specialization. Altura is ... , In earning the Select Certification, Altura fulfilled the training and ...
Breaking Medicine News(10 mins):